Promomed, LLC
10
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
90%
9 trials in Phase 3/4
20%
2 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity
Role: lead
Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After COVID-19
Role: lead
Efficacy of the Therapy With BRAINMAX® Using fMRI for the Treatment of Patients With Asthenia After COVID-19
Role: lead
Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity
Role: lead
Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population
Role: lead
Efficacy and Safety of Ambervin® and Standard Therapy in Hospitalized Patients With COVID-19
Role: lead
Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis
Role: lead
Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19
Role: lead
Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19
Role: lead
Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
Role: lead
All 10 trials loaded